KPRX

SEC source: 0001104659-20-057472 · tm2018856d3_4.xml · nonDerivative · entry 1

Mann Brenda · CIK 0001668858 · VP of Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,033

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 05/01/2020.

SEC source: 0001104659-20-057474 · tm2018856d4_4.xml · nonDerivative · entry 1

Romano Sarah · CIK 0001697536 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,397

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 05/01/2020.

SEC source: 0001104659-20-057471 · tm2018856d2_4.xml · nonDerivative · entry 1

MANZO MICHAEL P. · CIK 0001620189 · VP of Engineering

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,076

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 05/01/2020.

SEC source: 0001104659-20-057468 · tm2018856d1_4.xml · nonDerivative · entry 1

FROM STEPHEN · CIK 0001620137 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,330

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 05/01/2020.

SEC source: 0001104659-20-043264 · tm2014998d4_form4.xml · nonDerivative · entry 1

Mann Brenda · CIK 0001668858 · VP of Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,146

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 04/01/2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.96 to $5.09, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-20-043263 · tm2014998d3_form4.xml · nonDerivative · entry 1

FROM STEPHEN · CIK 0001620137 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,947

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 04/01/2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.96 to $5.12, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-20-043262 · tm2014998d2_form4.xml · nonDerivative · entry 1

MANZO MICHAEL P. · CIK 0001620189 · VP of Engineering

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,169

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 04/01/2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.96 to $5.12, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-20-043261 · tm2014998d1_form4.xml · nonDerivative · entry 1

Romano Sarah · CIK 0001697536 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,490

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 04/01/2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.96 to $5.09, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-20-031498 · tm2012338d3_4.xml · nonDerivative · entry 1

Mann Brenda · CIK 0001668858 · VP of Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,268

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 03/01/2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.00 to $5.01, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-20-031497 · tm2012338d2_4.xml · nonDerivative · entry 1

MANZO MICHAEL P. · CIK 0001620189 · VP of Engineering

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,291

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 03/01/2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.00 to $5.07, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-20-031499 · tm2012338d4_4.xml · nonDerivative · entry 1

FROM STEPHEN · CIK 0001620137 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 83,617

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 03/01/2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.00 to $5.05, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-20-031496 · tm2012338d1_4.xml · nonDerivative · entry 1

Romano Sarah · CIK 0001697536 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,612

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 03/01/2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.00 to $5.07, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-20-022841 · tm209305-2_4.xml · derivative · entry 2

Mann Brenda · CIK 0001668858 · VP of Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,500

Underlying: Common Stock · 7,500 shares

Expires 2030-02-14

F2 · derivative.exercise_date: The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Plan. The Option will become exercisable as to one-third (1/3) of the shares underlying the Option on February 1, 2021, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years.

SEC source: 0001104659-20-022841 · tm209305-2_4.xml · nonDerivative · entry 1

Mann Brenda · CIK 0001668858 · VP of Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,398

F1 · shares: Grant of restricted stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan (the "Plan"). The restrictions will vest as to one-third (1/3) of the shares on February 1, 2021, and the remaining balance will vest monthly on the first day of each calendar month thereafter for a period of two years.

SEC source: 0001104659-20-022846 · tm209305-6_4.xml · derivative · entry 1

TYLE PRAVEEN · CIK 0001296936 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,333

Underlying: Common Stock · 3,333 shares

Expires 2030-02-14

F1 · derivative.exercise_date: The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Plan. The Option will become fully exercisable on February 1, 2021.

SEC source: 0001104659-20-022845 · tm209305-5_4.xml · derivative · entry 1

CHANEY PAUL G · CIK 0001277477 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,333

Underlying: Common Stock · 3,333 shares

Expires 2030-02-14

F1 · derivative.exercise_date: The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Plan. The Option will become fully exercisable on February 1, 2021.

SEC source: 0001104659-20-022849 · tm209305-9_4.xml · derivative · entry 2

FROM STEPHEN · CIK 0001620137 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2030-02-14

F2 · derivative.exercise_date: The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Plan. The Option will become exercisable as to one-third (1/3) of the shares underlying the Option on February 1, 2021, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years.

SEC source: 0001104659-20-022849 · tm209305-9_4.xml · nonDerivative · entry 1

FROM STEPHEN · CIK 0001620137 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 84,329

F1 · shares: Grant of restricted stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan (the "Plan"). The restrictions will vest as to one-third (1/3) of the shares on February 1, 2021, and the remaining balance will vest monthly on the first day of each calendar month thereafter for a period of two years.

SEC source: 0001104659-20-022848 · tm209305-8_4.xml · derivative · entry 2

Romano Sarah · CIK 0001697536 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2030-02-14

F2 · derivative.exercise_date: The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Plan. The Option will become exercisable as to one-third (1/3) of the shares underlying the Option on February 1, 2021, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years.

SEC source: 0001104659-20-022848 · tm209305-8_4.xml · nonDerivative · entry 1

Romano Sarah · CIK 0001697536 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,742

F1 · shares: Grant of restricted stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan (the "Plan"). The restrictions will vest as to one-third (1/3) of the shares on February 1, 2021, and the remaining balance will vest monthly on the first day of each calendar month thereafter for a period of two years.

SEC source: 0001104659-20-022847 · tm209305-7_4.xml · derivative · entry 1

HANCOCK THOMAS · CIK 0001619727 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,333

Underlying: Common Stock · 3,333 shares

Expires 2030-02-14

F1 · derivative.exercise_date: The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Plan. The Option will become fully exercisable on February 1, 2021.

SEC source: 0001104659-20-022844 · tm209305-4_4.xml · derivative · entry 1

GOLDBERG MORTON · CIK 0001619731 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,333

Underlying: Common Stock · 3,333 shares

Expires 2030-02-14

F1 · derivative.exercise_date: The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Plan. The Option will become fully exercisable on February 1, 2021.

SEC source: 0001104659-20-022843 · tm209305-3_4.xml · derivative · entry 2

MANZO MICHAEL P. · CIK 0001620189 · VP of Engineering

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,500

Underlying: Common Stock · 7,500 shares

Expires 2030-02-14

F2 · derivative.exercise_date: The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Plan. The Option will become exercisable as to one-third (1/3) of the shares underlying the Option on February 1, 2021, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years.

SEC source: 0001104659-20-022843 · tm209305-3_4.xml · nonDerivative · entry 1

MANZO MICHAEL P. · CIK 0001620189 · VP of Engineering

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,421

F1 · shares: Grant of restricted stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan (the "Plan"). The restrictions will vest as to one-third (1/3) of the shares on February 1, 2021, and the remaining balance will vest monthly on the first day of each calendar month thereafter for a period of two years.

SEC source: 0001104659-20-022838 · tm209305-1_4.xml · derivative · entry 1

MALFROY-CAMINE BERNARD · CIK 0001619732 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,333

Underlying: Common Stock · 3,333 shares

Expires 2030-02-14

F1 · derivative.exercise_date: The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Plan. The Option will become fully exercisable on February 1, 2021.

SEC source: 0000919574-20-000888 · ownership.xml · nonDerivative · entry 4

ARMISTICE CAPITAL, LLC · CIK 0001601086 · Director · 10% owner

Armistice Capital Master Fund Ltd. · CIK 0001633584 · 10% owner

Boyd Steven · CIK 0001706140 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,815,500

F1 · ownership.nature: The reported securities are directly owned by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the "Master Fund"). The reported securities may be deemed to be indirectly beneficially owned by Armistice Capital, LLC ("Armistice Capital"), as the investment manager of the Master Fund. The reported securities may also be deemed to be indirectly beneficially owned by Steven Boyd as Managing Member of Armistice Capital. Armistice Capital and Steven Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interest therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

SEC source: 0000919574-20-000888 · ownership.xml · nonDerivative · entry 3

ARMISTICE CAPITAL, LLC · CIK 0001601086 · Director · 10% owner

Armistice Capital Master Fund Ltd. · CIK 0001633584 · 10% owner

Boyd Steven · CIK 0001706140 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,815,500

F3 · price: This constitutes the weighted average purchase price. The prices range from $5.93 to $6.11. The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

F1 · ownership.direct: The reported securities are directly owned by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the "Master Fund"). The reported securities may be deemed to be indirectly beneficially owned by Armistice Capital, LLC ("Armistice Capital"), as the investment manager of the Master Fund. The reported securities may also be deemed to be indirectly beneficially owned by Steven Boyd as Managing Member of Armistice Capital. Armistice Capital and Steven Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interest therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

SEC source: 0000919574-20-000888 · ownership.xml · nonDerivative · entry 2

ARMISTICE CAPITAL, LLC · CIK 0001601086 · Director · 10% owner

Armistice Capital Master Fund Ltd. · CIK 0001633584 · 10% owner

Boyd Steven · CIK 0001706140 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,803,500

F1 · ownership.nature: The reported securities are directly owned by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the "Master Fund"). The reported securities may be deemed to be indirectly beneficially owned by Armistice Capital, LLC ("Armistice Capital"), as the investment manager of the Master Fund. The reported securities may also be deemed to be indirectly beneficially owned by Steven Boyd as Managing Member of Armistice Capital. Armistice Capital and Steven Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interest therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

SEC source: 0000919574-20-000888 · ownership.xml · nonDerivative · entry 1

ARMISTICE CAPITAL, LLC · CIK 0001601086 · Director · 10% owner

Armistice Capital Master Fund Ltd. · CIK 0001633584 · 10% owner

Boyd Steven · CIK 0001706140 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,803,500

F2 · price: This constitutes the weighted average purchase price. The prices range from $6.16 to $6.23. The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

F1 · ownership.direct: The reported securities are directly owned by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the "Master Fund"). The reported securities may be deemed to be indirectly beneficially owned by Armistice Capital, LLC ("Armistice Capital"), as the investment manager of the Master Fund. The reported securities may also be deemed to be indirectly beneficially owned by Steven Boyd as Managing Member of Armistice Capital. Armistice Capital and Steven Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interest therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

SEC source: 0001104659-20-011324 · tm206871d2_4.xml · nonDerivative · entry 1

Mann Brenda · CIK 0001668858 · VP of Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,898

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 02/01/2020.

SEC source: 0001104659-20-011330 · tm206871d3_4.xml · nonDerivative · entry 1

MANZO MICHAEL P. · CIK 0001620189 · VP of Engineering

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,921

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 02/01/2020.

SEC source: 0001104659-20-011342 · tm206871d4_4.xml · nonDerivative · entry 1

FROM STEPHEN · CIK 0001620137 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,329

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 02/01/2020.

SEC source: 0001104659-20-011314 · tm206871d1_4.xml · nonDerivative · entry 1

Romano Sarah · CIK 0001697536 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,742

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 02/01/2020.

SEC source: 0001104659-20-001638 · tm201302-3_4.xml · nonDerivative · entry 1

Mann Brenda · CIK 0001668858 · VP of Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,007

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 01/01/2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.3537 to $9.52, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-20-001639 · tm201302-4_4.xml · nonDerivative · entry 1

FROM STEPHEN · CIK 0001620137 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,913

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 01/01/2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.395 to $9.52, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-20-001637 · tm201302-2_4.xml · nonDerivative · entry 1

Romano Sarah · CIK 0001697536 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,851

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 01/01/2020

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.3537 to $9.52, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-20-001636 · tm201302-1_4.xml · nonDerivative · entry 1

MANZO MICHAEL P. · CIK 0001620189 · VP of Engineering

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,030

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 01/01/2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.40 to $9.52, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-19-075133 · tm1926709d3_form4.xml · nonDerivative · entry 1

Mann Brenda · CIK 0001668858 · VP of Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,126

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 12/01/2019.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.46 to $7.47, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-19-075131 · tm1926709d2_form4.xml · nonDerivative · entry 1

MANZO MICHAEL P. · CIK 0001620189 · VP of Engineering

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,149

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 12/01/2019.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.46 to $7.47, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-19-075136 · tm1926709d4_form4.xml · nonDerivative · entry 1

Romano Sarah · CIK 0001697536 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,970

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 12/01/2019.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.46 to $7.53, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-19-075128 · tm1926709d1_form4.xml · nonDerivative · entry 1

FROM STEPHEN · CIK 0001620137 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,643

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 12/01/2019.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.46 to $7.48, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-19-070723 · tm1924718-1_4.xml · nonDerivative · entry 1

GOLDBERG MORTON · CIK 0001619731 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

SEC source: 0001104659-19-063335 · tm1922769-1_4.xml · nonDerivative · entry 1

GOLDBERG MORTON · CIK 0001619731 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,961

F1 · balance_after: Effective as of 08/30/2019, the Issuer effected a 1-for-15 reverse split of its common stock. The number of shares reflects the reverse stock split.

SEC source: 0001104659-19-061121 · tm1922166-1_4.xml · nonDerivative · entry 1

Mann Brenda · CIK 0001668858 · VP of Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,227

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 11/01/2019.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.85 to $3.92, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-19-061124 · tm1922166-4_4.xml · nonDerivative · entry 1

Romano Sarah · CIK 0001697536 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,071

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 11/01/2019.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.80 to $3.85, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-19-061123 · tm1922166-3_4.xml · nonDerivative · entry 1

MANZO MICHAEL P. · CIK 0001620189 · VP of Engineering

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,250

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 11/01/2019.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.85 to $4.00, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-19-061122 · tm1922166-2_4.xml · nonDerivative · entry 1

FROM STEPHEN · CIK 0001620137 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,296

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 11/01/2019.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.85 to $4.00, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001144204-19-048121 · tv530954_4.xml · nonDerivative · entry 1

Mann Brenda · CIK 0001668858 · VP of Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,334

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 09/01/2019 and 10/01/2019.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.92 to $3.39, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

F3 · balance_after: Effective as of 08/30/2019, the Issuer effected a 1-for-15 reverse split of its common stock. The number of shares reflects the reverse stock split.

SEC source: 0001144204-19-048122 · tv530955_4.xml · nonDerivative · entry 1

FROM STEPHEN · CIK 0001620137 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,966

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 09/01/2019 and 10/01/2019.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.89 to $3.02, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

F3 · balance_after: Effective as of 08/30/2019, the Issuer effected a 1-for-15 reverse split of its common stock. The number of shares reflects the reverse stock split.

SEC source: 0001144204-19-048123 · tv530956_4.xml · nonDerivative · entry 1

Romano Sarah · CIK 0001697536 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,179

F1 · kind: Sale of shares to cover taxes due on restricted stock that vested on 09/01/2019 and 10/01/2019.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.90 to $3.37, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

F3 · balance_after: Effective as of 08/30/2019, the Issuer effected a 1-for-15 reverse split of its common stock. The number of shares reflects the reverse stock split.